Aldeyra The

ALDX

$1.48

-0.67%

N/A-$0.01

Healthcare

Biotechnology

NASDAQ

Active Trading

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a ...

Financial Highlights of ALDX

Profitability trend

Latest / TTM · 6 periods

Gross Margin

0.0%

Net Margin

0.0%

P/E Ratio

-3.82x

n/a

Debt / Equity

0.00

n/a

Current Ratio

4.91

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Financial highlights

Latest / TTM · 6 periods

Snapshot

Latest / TTM: 2026-09-04

Gross Margin

0.0%

Net Margin

0.0%

P/E Ratio

-3.82x

Debt / Equity

0.00

Profitability

Profitability table

Metric	2021	2022	2023	2024	2025	2026
Gross MarginGross profit as a percentage of revenue.	0.0%	0.0%	0.0%	0.0%	0.0%	—
Operating MarginOperating income as a percentage of revenue.	0.0%	0.0%	0.0%	0.0%	0.0%	—
Net MarginNet income as a percentage of revenue.	0.0%	0.0%	0.0%	0.0%	0.0%	—
EBITDA MarginEBITDA divided by revenue.	0.0%	0.0%	0.0%	0.0%	0.0%	—
Pre-tax MarginPre-tax profit as a percentage of revenue.	0.0%	0.0%	0.0%	0.0%	0.0%	—

Liquidity & leverage

Liquidity & leverage table

Metric	2021	2022	2023	2024	2025	2026
Current RatioCurrent assets divided by current liabilities.	19.77	11.78	6.64	5.59	2.58	—
Quick RatioLiquid assets divided by current liabilities.	19.77	11.78	6.64	5.59	2.58	—
Cash RatioCash and equivalents divided by current liabilities.	19.52	9.40	6.42	2.93	2.52	—
Debt / AssetsDebt as a share of total assets.	6.8%	8.9%	10.6%	14.6%	21.6%	—
Debt / EquityDebt compared with shareholder equity.	0.08	0.11	0.13	0.22	0.35	—

Operating efficiency

Operating efficiency table

Metric	2021	2022	2023	2024	2025	2026
Receivables TurnoverHow often receivables are collected in a year.	0.00x	0.00x	0.00x	0.00x	0.00x	—
Inventory TurnoverHow often inventory is sold in a year.	0.00x	0.00x	0.00x	0.00x	0.00x	—
Payables TurnoverHow often payables are paid in a year.	0.00x	0.00x	0.00x	0.00x	0.00x	—
Asset TurnoverRevenue generated per dollar of assets.	0.00x	0.00x	0.00x	0.00x	0.00x	—
Working Capital TurnoverRevenue generated per dollar of working capital.	0.00x	0.00x	0.00x	0.00x	0.00x	—

Valuation ratios

Valuation ratios table

Metric	2021	2022	2023	2024	2025	2026
P/E RatioPrice paid for each dollar of earnings.	-3.74x	-6.57x	-5.48x	-5.31x	-9.25x	—
P/B RatioPrice paid for each dollar of book value.	1.05x	2.69x	1.73x	4.18x	7.03x	—
P/S RatioPrice paid for each dollar of sales.	0.00x	0.00x	0.00x	0.00x	0.00x	—
P/FCF RatioPrice paid for each dollar of free cash flow.	-5.08x	-7.18x	-6.82x	-6.87x	-9.33x	—
Dividend YieldAnnual dividend divided by current share price.	0.0%	0.0%	0.0%	0.0%	0.0%	—

Upstream

AbbVie Inc.NYSE:ABBV Janssen Research & Development (Johnson & Johnson)NYSE:JNJUnnamed Contract Manufacturing Organizations (CMOs/CDMOs)Unnamed API / Excipient Raw Material SuppliersUnnamed Clinical Research Organizations (CROs)

Downstream

AbbVie Inc.NYSE:ABBV Janssen Research & Development (Johnson & Johnson)NYSE:JNJPharmaceutical Wholesalers (Undefined — Pre-Commercial)

Proxies

Tarsus Pharmaceuticals, Inc.NASDAQ:TARS Kala Pharmaceuticals, Inc.NASDAQ:KALA Ocular Therapeutix, Inc.NASDAQ:OCUL

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

No matching stocks found

Aldeyra The

Financial Highlights of ALDX

Financial highlights

Snapshot

Profitability

Liquidity & leverage

Operating efficiency

Valuation ratios

Supply Chain of ALDX

Upstream

Downstream

Proxies

Financial Highlights of ALDX

Financial highlights

Snapshot

Profitability

Liquidity & leverage

Operating efficiency

Valuation ratios

Supply Chain of ALDX

Upstream

Downstream

Proxies